Continuous hemodiafiltration therapy reduces damage of multi-organs by ameliorating of HMGB1/TLR4/ NFκB in a dog sepsis model

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 2, 2015, Pages 1555-1564

  Sun, Jing ^a   Shi, Shaolan ^a   Wang, Qun ^a   Yu, Kezhou ^a   Wang, Rong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

CVVH; HMGB1; NF B; Sepsis; TLR4

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR 4;

ANIMAL; BLOOD; DISEASE MODEL; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIAFILTRATION; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMODIAFILTRATION; HMGB1 PROTEIN; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEPSIS; TOLL-LIKE RECEPTOR 4;

EID: 84928102563     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bae JS. Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch Pharm Res 2012; 35: 1511-1523.
2. Tang D, Kang R, Zeh HJ 3rd and Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 2011; 14: 1315-1335.
3. Jung HS, Joo JD, Kim DW, In JH, Roh M, Jeong JT, Noh SJ and Choi JW. Effect of milrinone on the inflammatory response and NF-κB activation in renal ischemia-reperfusion injury in mice. Korean J Anesthesiol 2014; 66: 136-142.
4. Uzawa A, Mori M, Taniguchi J, Masuda S, Muto M and Kuwabara S. Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clin Exp Immunol 2013; 172: 37-43.
5. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L and Treutiger CJ. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33: 564-573.
6. Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B and Bollaert PE. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med 2007; 33: 1347-1353.
7. Shen M, Lu J, Dai W, Wang F, Xu L, Chen K, He L, Cheng P, Zhang Y, Wang C, Wu D, Yang J, Zhu R, Zhang H, Zhou Y and Guo C. Ethyl pyruvate ameliorates hepatic ischemia-reperfusion injury by inhibiting intrinsic pathway of apoptosis and autophagy. Mediators Inflam 2013; 2013: 461536.
8. Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, Xia J and Fissell WH. Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 2003; 31: 2421-2428.
9. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN and Traber DL. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002; 18: 236-241.
10. Heijnen BH, Straatsburg IH, Gouma DJ and van Gulik TM. Decrease in core liver temperature with 10 degrees C by in situ hypothermic perfusion under total hepatic vascular exclusion reduces liver ischemia and reperfusion injury during partial hepatectomy in pigs. Surgery 2003; 134: 806-817.
11. Rabb H, O'Meara YM, Maderna P, Coleman P and Brady HR. Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int 1997; 51: 1463-1468.
12. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ and Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 2003; 284: C870-879.
13. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH and Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-2660.
14. He GZ, Zhou KG, Zhang R, Wang YK and Chen XF. Impact of intestinal ischemia/reperfusion and lymph drainage on distant organs in rats. World J Gastroenterol 2012; 18: 7271-7278.
15. Tong Y, Tang Z, Yang T, Yang Y, Yang L, Shen W and Chen W. Ulinastatin preconditioning attenuates inflammatory reaction of hepatic ischemia reperfusion injury in rats via high mobility group box 1 (HMGB1) inhibition. Int J Med Sci 2014; 11: 337-343.
16. Chagnon F, Metz CN, Bucala R and Lesur O. Endotoxin-induced myocardial dysfunction effects of macrophage migration inhibitory factor neutralization. Circ Res 2005; 96: 1095-1102.
17. Chen D, Bellussi LM, Passali D and Chen L. LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro. Acta Otorhinolaryngol Ital 2013; 33: 398-404.
18. Nishiike S, Hiramatsu T, Shiraishi M, Ueda Y and Tsuchida H. Relationship between vascular reactivity and expression of HMGB1 in a rat model of septic aorta. J Anesth 2013; 27: 684-692.
19. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, Melloni E and Presta M. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006; 176: 12-15.
20. Yanai H, Matsuda A, An J, Koshiba R, Nishio J, Negishi H, Ikushima H, Onoe T, Ohdan H, Yoshida N and Taniguchi T. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc Natl Acad Sci U S A 2013; 110: 20699-20704.
21. Aller MA, Arias JI, Alonso-Poza A and Arias J. A review of metabolic staging in severely injured patients. Scand J Trauma Resusc Emerg Med 2010; 18: 27.
22. Comstedt P, Storgaard M and Lassen AT. The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study. Scand J Trauma Resusc Emerg Med 2009; 17: 67.
23. Xu D, Young J, Song D and Esko JD. Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J Biol Chem 2011; 286: 41736-41744.
24. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A and Abraham E. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917-924.
25. Velegraki M, Papakonstanti E, Mavroudi I, Psyllaki M, Tsatsanis C, Oulas A, Iliopoulos I, Katonis P and Papadaki HA. Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production. Haematologica 2013; 98: 1206-1215.
26. Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S, Xiang J, Li JC, Fang CQ and Wang JZ. HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 2011; 31: 593-605.
27. Palumbo R, Galvez BG, Pusterla T, De Marchis F, Cossu G, Marcu KB and Bianchi ME. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-κB activation. J Cell Biol 2007; 179: 33-40.
28. McCauley MJ, Rueter EM, Rouzina I, Maher LJ 3rd and Williams MC. Single-molecule kinetics reveal microscopic mechanism by which High-Mobility Group B proteins alter DNA flexibility. Nucleic Acids Res 2013; 41: 167-181.
29. Chen G, Zhang S, Shi J, Ai J, Qi M and Hang C. Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-kappaB pathway. Exp Neurol 2009; 216: 398-406.
30. Nace GW, Huang H, Klune JR, Eid RE, Rosborough BR, Korff S, Li S, Shapiro RA, Stolz DB, Sodhi CP, Hackam DJ, Geller DA, Billiar TR and Tsung A. Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury. Hepatology 2013; 58: 374-387.
31. Rabadi MM, Ghaly T, Goligorksy MS and Ratliff BB. HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol 2012; 303: F873-885.
32. Ha T, Xia Y, Liu X, Lu C, Liu L, Kelley J, Kalbfleisch J, Kao RL, Williams DL and Li C. Glucan phosphate attenuates myocardial HMGB1 translocation in severe sepsis through inhibiting NF-κB activation. Am J Physiol Heart Circ Physiol 2011; 301: H848-855.